FDA proposes registration and drug listing rules for bulk substances used in compounding, with operational changes for establishments engaged in producing active ingredients

FDA drug establishment registration and drug listing requirements are the focus of this proposed rule for establishments engaged in manufacturing bulk drug substances used in compounding. The change centers on when and how facilities must register, list products, and comply with federal reporting obligations tied to active pharmaceutical ingredient production. Bulk substance manufacturers that supply compounders could face updated administrative and compliance duties, including clearer expectations for identifying operations and products within FDA systems. The rule sits at the intersection of supply chain oversight, manufacturing accountability, and product traceability rather than psychedelic practice or culture. The practical significance lies in tighter federal visibility into ingredient production for compounded medicines, which can affect enforcement, market access, and quality assurance across pharmaceutical manufacturing networks.